| Sharon R Androes, | |
|
465 Leisure Dr, Kalispell, MT 59901-7587 | |
| (406) 752-3413 | |
| Not Available |
| Full Name | Sharon R Androes |
|---|---|
| Gender | Female |
| Speciality | Clinical Nurse Specialist - Psychiatric/mental Health, Adult |
| Location | 465 Leisure Dr, Kalispell, Montana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1689720013 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SP0809X | Clinical Nurse Specialist - Psychiatric/mental Health, Adult | 8385 (Montana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Sharon R Androes, Po Box 3277, Kalispell, MT 59903-3277 Ph: (406) 752-3413 | Sharon R Androes, 465 Leisure Dr, Kalispell, MT 59901-7587 Ph: (406) 752-3413 |
News Archive
Athletes with a vocal cord disorder that restricts breathing are more likely to be misdiagnosed and inappropriately treated for exercise-induced asthma, according to research presented today at the Triological Society's 116th Annual Meeting.
Metabolex and Sanofi-Aventis announced today that they have entered into a global license and development agreement for the research, development, manufacture and commercialization of small molecules that modulate the G-protein coupled receptor 119 (GPR119), a receptor in the gut and pancreas that interacts with bioactive lipids to stimulate glucose-dependent incretin and insulin secretion.
New University of Liverpool research, published in Pediatrics, highlights the negative influence that social media has on children's food intake.
NewLink Genetics Corporation announced today that it has closed a $30 million Series C financing to accelerate the clinical development of its therapeutic cancer products. Total cash raised in 2009 under a combination of the previously announced Series D Preferred and the remaining shares in the Series C Preferred totaled just under $20 million.
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has entered into a settlement agreement with OSI, Pfizer and Genentech that will resolve patent litigation related to Erlotinib Hydrochloride Tablets, 25 mg, 100 mg and 150 mg.
› Verified 3 days ago
Susan E Bodurtha, RN, CNS Clinical Nurse Specialist Medicare: Medicare Enrolled Practice Location: 410 Windward Way, Kalispell, MT 59901 Phone: 406-257-1336 Fax: 406-257-1353 | |
Sara Richardson, AGCNS Clinical Nurse Specialist Medicare: Medicare Enrolled Practice Location: 310 Sunnyview Ln, Kalispell, MT 59901 Phone: 406-751-6725 Fax: 406-758-5170 |